Abstract
RNA interference (RNAi) is a conserved mechanism for post-transcriptional gene silencing mediated by messenger RNA (mRNA) degradation. RNAi is commonly induced by synthetic siRNA or shRNA which recognizes the targeted mRNA by base pairing and leads to target-mRNA degradation. RNAi may discriminate between two sequences only differing by one nucleotide conferring a high specificity of RNAi for its target mRNA. This property was used to develop a particular therapeutic strategy called “allele-specific-RNA interference” devoted to silence the mutated allele of genes causing dominant inherited diseases without affecting the normal allele. Therapeutic benefit was now demonstrated in cells from patients and animal models, and promising results of the first phase Ib clinical trial using siRNA-based allele-specific therapy were reported in Pachyonychia Congenita, an inherited skin disorder due to dominant mutations in the Keratin 6 gene. Our purpose is to review the successes of this strategy aiming to treat dominant inherited diseases and to highlight the pitfalls to avoid.
Keywords: Allele-specific silencing, Dominant inherited diseases, Pitfalls, RNA interference, Single nucleotide substitution, Gene-based therapy.
Current Gene Therapy
Title:Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Volume: 15 Issue: 5
Author(s): Delphine Trochet, Bernard Prudhon, Stéphane Vassilopoulos and Marc Bitoun
Affiliation:
Keywords: Allele-specific silencing, Dominant inherited diseases, Pitfalls, RNA interference, Single nucleotide substitution, Gene-based therapy.
Abstract: RNA interference (RNAi) is a conserved mechanism for post-transcriptional gene silencing mediated by messenger RNA (mRNA) degradation. RNAi is commonly induced by synthetic siRNA or shRNA which recognizes the targeted mRNA by base pairing and leads to target-mRNA degradation. RNAi may discriminate between two sequences only differing by one nucleotide conferring a high specificity of RNAi for its target mRNA. This property was used to develop a particular therapeutic strategy called “allele-specific-RNA interference” devoted to silence the mutated allele of genes causing dominant inherited diseases without affecting the normal allele. Therapeutic benefit was now demonstrated in cells from patients and animal models, and promising results of the first phase Ib clinical trial using siRNA-based allele-specific therapy were reported in Pachyonychia Congenita, an inherited skin disorder due to dominant mutations in the Keratin 6 gene. Our purpose is to review the successes of this strategy aiming to treat dominant inherited diseases and to highlight the pitfalls to avoid.
Export Options
About this article
Cite this article as:
Trochet Delphine, Prudhon Bernard, Vassilopoulos Stéphane and Bitoun Marc, Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls, Current Gene Therapy 2015; 15 (5) . https://dx.doi.org/10.2174/1566523215666150812115730
DOI https://dx.doi.org/10.2174/1566523215666150812115730 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases – Part I
Current Medicinal Chemistry Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets The Cardiac Conduction and Contractility Complications of Methamphetamine Use and the Relationship to Psychiatric Comorbidity: A Systematic Review
Current Psychiatry Research and Reviews Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress
Current Pharmaceutical Design Cardiac Innervation and Sudden Cardiac Death
Current Cardiology Reviews Heat Shock Protein-60 and Risk for Cardiovascular Disease
Current Pharmaceutical Design New Approach to Immunotherapy Against Organ-specific Autoimmune Diseases with T Cell Receptor and Chemokine Receptor DNA Vaccines
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
Current Drug Metabolism Dynamics of T Cells Repertoire During Trypanosoma cruzi Infection and its Post-Treatment Modulation
Current Medicinal Chemistry Mechanical Circulatory Support in Children
Current Cardiology Reviews Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Current Drug Metabolism Therapeutic Angiogenesis by Gene Therapy for Critical Limb Ischemia: Choice of Biological Agent
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Vascular Pathology from Smoking: Look at the Microcirculation!
Current Vascular Pharmacology Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure
Current Vascular Pharmacology Genetics of Primary CoQ10 Deficiency
Current Genomics Cardiac Stem Cell Regeneration in Metabolic Syndrome
Current Pharmaceutical Design Transient Receptor Potential (TRP) Channels and Cardiac Fibrosis
Current Topics in Medicinal Chemistry Oncolytic Coxsackievirus and the Mechanisms of its Effects on Cancer: A Narrative Review
Current Cancer Therapy Reviews Monoclonal Antibody-Based Targeted Therapy in Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry